These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2427 related articles for article (PubMed ID: 32063474)

  • 21. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
    Frank MJ; Baird JH; Kramer AM; Srinagesh HK; Patel S; Brown AK; Oak JS; Younes SF; Natkunam Y; Hamilton MP; Su YJ; Agarwal N; Chinnasamy H; Egeler E; Mavroukakis S; Feldman SA; Sahaf B; Mackall CL; Muffly L; Miklos DB;
    Lancet; 2024 Jul; 404(10450):353-363. PubMed ID: 38996463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
    Wang N; Meng Y; Wu Y; He J; Liu F
    Immunotherapy; 2021 Mar; 13(4):345-357. PubMed ID: 33406914
    [No Abstract]   [Full Text] [Related]  

  • 23. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
    Pan J; Niu Q; Deng B; Liu S; Wu T; Gao Z; Liu Z; Zhang Y; Qu X; Zhang Y; Liu S; Ling Z; Lin Y; Zhao Y; Song Y; Tan X; Zhang Y; Li Z; Yin Z; Chen B; Yu X; Yan J; Zheng Q; Zhou X; Gao J; Chang AH; Feng X; Tong C
    Leukemia; 2019 Dec; 33(12):2854-2866. PubMed ID: 31110217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
    Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
    Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
    Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
    Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
    Tong C; Zhang Y; Liu Y; Ji X; Zhang W; Guo Y; Han X; Ti D; Dai H; Wang C; Yang Q; Liu W; Wang Y; Wu Z; Han W
    Blood; 2020 Oct; 136(14):1632-1644. PubMed ID: 32556247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
    Chong EA; Alanio C; Svoboda J; Nasta SD; Landsburg DJ; Lacey SF; Ruella M; Bhattacharyya S; Wherry EJ; Schuster SJ
    Blood; 2022 Feb; 139(7):1026-1038. PubMed ID: 34496014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.
    Xin X; Zhu X; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Li C; Cao Y; Meng F; Jiang L; Zhang Y
    Cell Oncol (Dordr); 2024 Aug; 47(4):1425-1440. PubMed ID: 38564164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.
    Wei J; Zhu X; Mao X; Huang L; Meng F; Zhou J
    J Immunother Cancer; 2019 Nov; 7(1):315. PubMed ID: 31753002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 122.